X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3064) 3064
Book Review (444) 444
Newsletter (114) 114
Publication (109) 109
Conference Proceeding (20) 20
Magazine Article (20) 20
Book Chapter (18) 18
Newspaper Article (14) 14
Dissertation (7) 7
Trade Publication Article (4) 4
Web Resource (2) 2
Data Set (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
sitagliptin (2353) 2353
index medicus (1938) 1938
humans (1627) 1627
diabetes mellitus, type 2 - drug therapy (1212) 1212
type 2 diabetes (1151) 1151
male (1104) 1104
endocrinology & metabolism (896) 896
female (889) 889
diabetes (864) 864
sitagliptin phosphate (822) 822
hypoglycemic agents - therapeutic use (805) 805
middle aged (771) 771
metformin (657) 657
dipeptidyl-peptidase iv inhibitors - therapeutic use (597) 597
aged (577) 577
glucose (500) 500
animals (485) 485
pharmacology & pharmacy (478) 478
glycemic control (475) 475
treatment outcome (473) 473
glucagon-like peptide-1 (470) 470
dipeptidyl peptidase-4 inhibitor (462) 462
safety (446) 446
pyrazines - therapeutic use (436) 436
triazoles - therapeutic use (436) 436
hypoglycemic agents (434) 434
diabetes mellitus, type 2 - blood (432) 432
efficacy (430) 430
double-blind (427) 427
adult (424) 424
insulin (402) 402
diabetes mellitus (390) 390
hypoglycemic agents - adverse effects (385) 385
care and treatment (379) 379
research (376) 376
drug therapy, combination (344) 344
hypoglycemic agents - administration & dosage (341) 341
drug therapy (337) 337
analysis (336) 336
dipeptidyl-peptidase iv inhibitors - pharmacology (329) 329
blood glucose - metabolism (324) 324
diabetes therapy (321) 321
vildagliptin (321) 321
blood glucose - drug effects (307) 307
type 2 diabetes mellitus (300) 300
medicine, general & internal (286) 286
mellitus (284) 284
liraglutide (271) 271
dipeptidyl-peptidase iv inhibitors - adverse effects (264) 264
sitagliptin phosphate - therapeutic use (261) 261
exenatide (260) 260
risk factors (259) 259
dosage and administration (258) 258
metformin - therapeutic use (255) 255
glycated hemoglobin a - metabolism (252) 252
double-blind method (244) 244
internal medicine (244) 244
clinical trials (243) 243
hypoglycemic agents - pharmacology (238) 238
type-2 diabetes-mellitus (234) 234
rats (230) 230
triazoles - pharmacology (229) 229
dextrose (228) 228
pyrazines - pharmacology (228) 228
monotherapy (218) 218
dipeptidyl peptidase-4 inhibitors (216) 216
dpp-4 inhibitor (215) 215
adamantane - analogs & derivatives (213) 213
mice (210) 210
diabetes mellitus, type 2 - complications (208) 208
therapy (207) 207
triazoles - administration & dosage (204) 204
pyrazines - administration & dosage (203) 203
dipeptidyl-peptidase iv inhibitors - administration & dosage (199) 199
hypoglycemia (192) 192
saxagliptin (192) 192
beta-cell function (190) 190
glp-1 (189) 189
glucagon (187) 187
dipeptidyl peptidase 4 - metabolism (186) 186
hyperglycemia (185) 185
pyrazines - adverse effects (185) 185
triazoles - adverse effects (183) 183
medicine & public health (182) 182
risk (181) 181
abridged index medicus (178) 178
medicine, research & experimental (177) 177
health aspects (170) 170
glycosylated hemoglobin (167) 167
insulin resistance (167) 167
medical research (166) 166
linagliptin (161) 161
complications and side effects (160) 160
peptides (157) 157
cardiac & cardiovascular systems (151) 151
glycated hemoglobin a - analysis (148) 148
peptidase (146) 146
dpp-4 inhibitors (144) 144
adamantane - therapeutic use (143) 143
pharmacokinetics (143) 143
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3069) 3069
German (51) 51
French (29) 29
Spanish (15) 15
Hungarian (14) 14
Korean (14) 14
Chinese (12) 12
Czech (10) 10
Japanese (10) 10
Russian (7) 7
Dutch (3) 3
Italian (3) 3
Portuguese (2) 2
Swedish (2) 2
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 07/2015, Volume 373, Issue 3, pp. 232 - 242
Journal Article
10/2011
Sitagliptin is a newer oral hypoglycemic drug of the dipeptidyl peptidase-IV inhibitor class. It appears to be a promising newer oral hypoglycemic agent. The... 
sitagliptin | Dipeptidyl peptidase inhibitor | hemolysis
Web Resource
Photodermatology, Photoimmunology & Photomedicine, ISSN 0905-4383, 09/2019, Volume 35, Issue 5, pp. 375 - 377
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 08/2018, Volume 20, Issue 8, pp. 1921 - 1927
Aims The recent LIRA-SWITCH trial showed that switching from sitagliptin 100 mg to liraglutide 1.8 mg led to statistically significant and clinically relevant... 
cost‐effectiveness | GLP‐1 analogue | type 2 diabetes | incretin therapy | liraglutide, sitagliptin | cost-effectiveness | GLP-1 analogue | liraglutide | VALIDATION | UTILITY VALUES | MELLITUS | MODEL | sitagliptin | DISEASE | ENDOCRINOLOGY & METABOLISM | MULTIFACTORIAL INTERVENTION | COMPLICATIONS | OUTCOMES | Anti-Obesity Agents - economics | Hypoglycemia - therapy | Overweight - complications | Hypoglycemic Agents - economics | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Overweight - drug therapy | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Anti-Obesity Agents - adverse effects | Diabetes Mellitus, Type 2 - economics | Diabetes Complications - therapy | Diabetes Mellitus, Type 2 - metabolism | Models, Economic | Weight Loss - drug effects | Anti-Obesity Agents - therapeutic use | Liraglutide - economics | Dipeptidyl-Peptidase IV Inhibitors - economics | Hypoglycemia - prevention & control | Overweight - metabolism | Glucagon-Like Peptide-1 Receptor - metabolism | Diabetes Complications - epidemiology | Hypoglycemia - economics | Hypoglycemia - chemically induced | Overweight - economics | Diabetes Mellitus, Type 2 - complications | Drug Resistance | Diabetes Complications - prevention & control | Body Mass Index | Hypoglycemic Agents - therapeutic use | Hyperglycemia - prevention & control | Hyperglycemia - economics | Risk Factors | Sitagliptin Phosphate - economics | Diabetes Complications - economics | Health Care Costs | Liraglutide - adverse effects | Cost-Benefit Analysis | Liraglutide - therapeutic use | Quality of Life | Sitagliptin Phosphate - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Drug Monitoring | Hyperglycemia - therapy | Hypoglycemic Agents - adverse effects | United Kingdom - epidemiology | Glucagon-Like Peptide-1 Receptor - agonists | Cohort Studies | Sitagliptin Phosphate - adverse effects | Type 2 diabetes | Glycosylated hemoglobin | Hypoglycemic agents | Cost benefit analysis | Health aspects | Analysis | Body mass index | Costs | Statistical analysis | Life span | Diabetes mellitus | Hemoglobin | Diabetes | Diabetes mellitus (non-insulin dependent) | Patients | Clinical outcomes | Index Medicus
Journal Article
Diabetes Care, ISSN 0149-5992, 2014, Volume 37, Issue 8, pp. 2149 - 2158
OBJECTIVE To compare the efficacy and safety of two doses of once-weekly dulaglutide, a glucagon-like peptide 1 receptor agonist, to sitagliptin in... 
METFORMIN | GLYCEMIC CONTROL | PLACEBO | GLP-1 | GLUCAGON-LIKE PEPTIDE-1 | RECEPTOR AGONISTS | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | ANALOG LIRAGLUTIDE | OPEN-LABEL | INHIBITOR SITAGLIPTIN | Glycated Hemoglobin A - analysis | Triazoles - administration & dosage | Triazoles - adverse effects | Recombinant Fusion Proteins - adverse effects | Glucagon-Like Peptides - administration & dosage | Humans | Middle Aged | Pyrazines - administration & dosage | Male | Immunoglobulin Fc Fragments - administration & dosage | Dose-Response Relationship, Drug | Hypoglycemic Agents - administration & dosage | Female | Metformin - administration & dosage | Sitagliptin Phosphate | Drug Therapy, Combination | Glucagon-Like Peptides - analogs & derivatives | Immunoglobulin Fc Fragments - adverse effects | Recombinant Fusion Proteins - administration & dosage | Double-Blind Method | Treatment Outcome | Blood Glucose - drug effects | Glucagon-Like Peptides - adverse effects | Pyrazines - adverse effects | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Glucagon-Like Peptide 1 - therapeutic use | Type 2 diabetes | Sitagliptin | Care and treatment | Dosage and administration | Safety and security measures | Comparative analysis | Clinical trials | Hemoglobin | Glycosylation | Diabetes | Product safety | Placebo effect | Index Medicus | Psychosocial Research | Nutrition | Education | Clinical Care
Journal Article
Diabetes Care, ISSN 0149-5992, 03/2016, Volume 39, Issue 3, pp. 455 - 464
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 02/2018, Volume 20, Issue 2, pp. 378 - 388
Aims: To assess the safety and efficacy of monotherapy with once-weekly subcutaneous (s.c.) semaglutide vs sitagliptin in Japanese people with type 2 diabetes... 
GLP | sitagliptin | type 2 diabetes | GLP-1 | METFORMIN | ADD-ON | AMERICAN ASSOCIATION | HUMAN GLP-1 ANALOG | EXENATIDE | PHASE 3A | OPEN-LABEL | CLINICAL ENDOCRINOLOGISTS | LIRAGLUTIDE | ENDOCRINOLOGY & METABOLISM | ACUTE-PANCREATITIS | Glycated Hemoglobin A - analysis | Follow-Up Studies | Nausea - chemically induced | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Diarrhea - physiopathology | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Glucagon-Like Peptides - administration & dosage | Humans | Nausea - physiopathology | Patient Dropouts | Weight Loss - drug effects | Diarrhea - chemically induced | Dose-Response Relationship, Drug | Hypoglycemia - prevention & control | Diabetes Mellitus, Type 2 - ethnology | Glucagon-Like Peptide-1 Receptor - metabolism | Nausea - therapy | Injections, Subcutaneous | Hypoglycemia - chemically induced | Severity of Illness Index | Sitagliptin Phosphate - administration & dosage | Hyperglycemia - prevention & control | Drug Administration Schedule | Administration, Oral | Japan | Constipation - physiopathology | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Constipation - chemically induced | Glucagon-Like Peptides - adverse effects | Diabetes Mellitus, Type 2 - blood | Diarrhea - therapy | Constipation - therapy | Incretins - adverse effects | Sitagliptin Phosphate - therapeutic use | Glucagon-Like Peptides - therapeutic use | Incretins - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide-1 Receptor - agonists | Incretins - administration & dosage | Sitagliptin Phosphate - adverse effects | Type 2 diabetes | Glycosylated hemoglobin | Hypoglycemic agents | Glucagon | Diabetes mellitus | Body weight | Hemoglobin | Diabetes | Safety | Diabetes mellitus (non-insulin dependent) | Glucagon-like peptide 1 | Index Medicus | GLP‐1 | Original
Journal Article
Artificial Cells, Nanomedicine, and Biotechnology, ISSN 2169-1401, 10/2018, Volume 46, Issue 1, pp. 66 - 78
Journal Article
Diabetic Medicine, ISSN 0742-3071, 04/2016, Volume 33, Issue 4, pp. 471 - 477
The study is unique in reporting resource use associated with severe hypoglycaemia from a randomized controlled trial setting, because resource use has... 
GLYCEMIC CONTROL | 26-WEEK | GLARGINE | NAIVE PATIENTS | ENDOCRINOLOGY & METABOLISM | NON-INFERIORITY TRIAL | OPEN-LABEL | TO-TARGET TRIAL | BASAL-BOLUS TREATMENT | TYPE-2 | DEGLUDEC/INSULIN ASPART | Hypoglycemia - therapy | Hypoglycemic Agents - economics | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Insulin Detemir - therapeutic use | Insulin Detemir - economics | Clinical Trials, Phase III as Topic | Hypoglycemic Agents - administration & dosage | Hypoglycemic Agents - therapeutic use | Sitagliptin Phosphate - administration & dosage | Costs and Cost Analysis | Administration, Oral | Drug Therapy, Combination - economics | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Insulin Aspart - economics | Insulin, Long-Acting - adverse effects | Insulin, Long-Acting - administration & dosage | Diabetes Mellitus, Type 1 - economics | Diabetes Mellitus, Type 1 - blood | Insulin, Long-Acting - therapeutic use | Hypoglycemic Agents - adverse effects | Insulin Aspart - adverse effects | Cohort Studies | Insulin Aspart - therapeutic use | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Diabetes Mellitus, Type 2 - economics | Insulin, Long-Acting - economics | Dipeptidyl-Peptidase IV Inhibitors - economics | Insulin Glargine - administration & dosage | Drug Therapy, Combination - adverse effects | Insulin Aspart - administration & dosage | Insulin Detemir - administration & dosage | Insulin Detemir - adverse effects | Hypoglycemia - physiopathology | Adult | Hypoglycemia - economics | Hypoglycemia - chemically induced | Severity of Illness Index | Insulin Glargine - adverse effects | Drug Administration Schedule | Insulin Glargine - economics | Insulin Glargine - therapeutic use | Sitagliptin Phosphate - economics | Diabetes Mellitus, Type 1 - drug therapy | Diabetes Mellitus, Type 2 - blood | Health Care Costs | Sitagliptin Phosphate - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Drug Combinations | Sitagliptin Phosphate - adverse effects | Type 2 diabetes | Adults | Type 1 diabetes | Insulin | Analysis | Emergency medical care | Diabetes | Hypoglycemia | Index Medicus | Complications | Research
Journal Article
Diabetes Care, ISSN 0149-5992, 2016, Volume 39, Issue 12, pp. 2304 - 2310
OBJECTIVE To evaluate chronic kidney disease (CKD) and cardiovascular outcomes in TECOS (Clinical trial reg. no. NCT00790205, clinicaltrials. gov) participants... 
MORTALITY | INDIVIDUALS | ASSOCIATIONS | ALBUMINURIA | GLUCOSE | ENDOCRINOLOGY & METABOLISM | RISK | HYPERTENSION | LINAGLIPTIN | INTERVENTION | STAGE RENAL-DISEASE | Sitagliptin Phosphate - pharmacology | Cardiovascular Diseases - prevention & control | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Male | Renal Insufficiency, Chronic - complications | Dipeptidyl-Peptidase IV Inhibitors - pharmacology | Diabetes Mellitus, Type 2 - epidemiology | Renal Insufficiency, Chronic - epidemiology | Cardiovascular Diseases - complications | Glomerular Filtration Rate - drug effects | Cardiovascular Diseases - epidemiology | Female | Diabetes Mellitus, Type 2 - complications | Kidney - physiopathology | Hypoglycemic Agents - therapeutic use | Kidney - drug effects | Double-Blind Method | Treatment Outcome | Renal Insufficiency, Chronic - physiopathology | Hypoglycemic Agents - pharmacology | Renal Insufficiency, Chronic - prevention & control | Diabetes Mellitus, Type 2 - physiopathology | Sitagliptin Phosphate - therapeutic use | Aged | Diabetes Mellitus, Type 2 - drug therapy | Type 2 diabetes | Complications and side effects | Care and treatment | Kidney function tests | Sitagliptin | Dosage and administration | Research | Cardiovascular disease | Glycemic index | Diabetes | Medical treatment | Index Medicus
Journal Article
Journal Article